Elevance Health (ELV) Is Up 6.7% After Raising 2026 EPS Outlook And Boosting Capital Returns – Has The Bull Case Changed?

Simply Wall St.05:09

Earlier this week, Elevance Health reported first-quarter 2026 results with revenue of US$50.18 billion and net income of US$1.76 billion, while also declaring a second-quarter dividend of US$1.72 per...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630802405?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160","is_english":true,"pubTime":"2026-04-26 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630802405","market":"hk","top_or_hot":-1,"title":"Elevance Health (ELV) Is Up 6.7% After Raising 2026 EPS Outlook And Boosting Capital Returns – Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this week, Elevance Health reported first-quarter 2026 results with revenue of US$50.18 billion and net income of US$1.76 billion, while also declaring a second-quarter dividend of US$1.72 per...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-is-up-67-after-raising-2026-eps-outlook\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elevance Health (ELV) Is Up 6.7% After Raising 2026 EPS Outlook And Boosting Capital Returns – Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElevance Health (ELV) Is Up 6.7% After Raising 2026 EPS Outlook And Boosting Capital Returns – Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-26 05:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-is-up-67-after-raising-2026-eps-outlook><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, Elevance Health reported first-quarter 2026 results with revenue of US$50.18 billion and net income of US$1.76 billion, while also declaring a second-quarter dividend of US$1.72 per...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-is-up-67-after-raising-2026-eps-outlook\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELV","symbol_name":"Elevance Health","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-is-up-67-after-raising-2026-eps-outlook","article_id":"2630802405","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/elevance-health-elv-is-up-67-after-raising-2026-eps-outlook","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630802405","pubTimestamp":1777151358,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this week, Elevance Health reported first-quarter 2026 results with revenue of US$50.18 billion and net income of US$1.76 billion, while also declaring a second-quarter dividend of US$1.72 per share and updating full-year 2026 diluted EPS guidance to at least US$19.85.\nBeneath the headline numbers, the quarter featured earnings that exceeded analyst expectations, a higher adjusted EPS outlook, and ongoing support from share repurchases that reduced the share count by 3,700,000 in the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ELV":"Elevance Health","ELV.AU":"ELEVRA LITHIUM LTD"},"translate_title":"Elevance Health(ELV)在上调2026年每股收益预期并提高资本回报后上涨6.7%——牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV.AU":1.5,"ELV":1.5},"content_text":"Earlier this week, Elevance Health reported first-quarter 2026 results with revenue of US$50.18 billion and net income of US$1.76 billion, while also declaring a second-quarter dividend of US$1.72 per share and updating full-year 2026 diluted EPS guidance to at least US$19.85. Beneath the headline numbers, the quarter featured earnings that exceeded analyst expectations, a higher adjusted EPS outlook, and ongoing support from share repurchases that reduced the share count by 3,700,000 in the first quarter alone. With Elevance Health lifting full-year adjusted EPS guidance, we’ll now examine how this stronger earnings outlook reshapes its investment narrative. Find 56 companies with promising cash flow potential yet trading below their fair value.AdvertisementElevance Health Investment Narrative RecapTo own Elevance Health, you need to believe its scale, government-backed membership, and Carelon services can offset policy uncertainty and elevated medical costs. The Q1 2026 beat and higher adjusted EPS outlook support the near term earnings catalyst, but do not remove the pressure from rising Medicaid and ACA medical trends, which remain the central risk to margins. The most relevant announcement here is the upgraded full year adjusted EPS guidance to at least US$26.75, alongside Q1 revenue of US$50.18 billion and non GAAP EPS of US$12.58. Together with US$1.10 billion of buybacks and the US$1.72 quarterly dividend, this guidance anchors the current earnings story while investors watch closely to see if medical cost trends and regulatory developments cooperate. Yet beneath this stronger earnings outlook, investors should still be aware of how persistent Medicaid and ACA medical cost pressures could... Read the full narrative on Elevance Health (it's free!)Elevance Health's narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and a $2.0 billion earnings increase from $5.4 billion today.Uncover how Elevance Health's forecasts yield a $387.85 fair value, a 12% upside to its current price.Exploring Other PerspectivesELV 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming Elevance could reach about US$7.5 billion in earnings by 2029, and this quarter’s stronger adjusted EPS plus the focus on value based care and AI may either reinforce or challenge that view, so it is worth looking at how differently you and those bullish analysts think about Elevance’s long term margin potential.Explore 11 other fair value estimates on Elevance Health - why the stock might be worth over 3x more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.Seeking Other Investments?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630802405","isCrawlerRequest":true}